About Technology Development
UT Southwestern Medical Center has been protecting and licensing intellectual property for more than 40 years. The Office for Technology Development (OTD) was created in 1998 to manage UT Southwestern's technology transfer activities and to facilitate the formation of biomedical companies based on UT Southwestern-developed technologies.
The Office for Technology Development transitioned its traditional business model in order to enhance and streamline operating efficiencies to provide a better experience for UT Southwestern researchers and external stakeholders. The entire team, including, but not limited to Assistant Directors of Technology Commercialization (ADCs), Commercialization Success Partners (CSPs), faculty liaisons and the business development team, serve as OTD Liaisons to engage collaboratively with faculty, clinicians, researchers and industry partners to better meet the needs of the increasingly complex research, technology development and commercialization relationships required to advance UT Southwestern's science into development for the benefit of patients.
Connect with your OTD Liaison to identify the name and point of contact information for your department.
Taysha Gene Therapies is a biotechnology company in Dallas, Texas focused on developing curative medicines for monogenic CNS diseases. The company has combined its experience in gene therapy drug development and commercialization with UT Southwestern’s Gene Therapy Program to build an extensive targeted pipeline focused on both rare and large-market indications. Through this alliance, Taysha is able to rapidly translate treatments from early discovery into the clinics for treatment of patients with progressive neurological disease.
Founded in 2020
OncoNano Medicine, located in Southlake, Texas, is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple, and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. The company’s lead program, ONM-100, targets tumor acidosis to accurately differentiate cancer from healthy tissue for use in surgery.
Founded in 2016
Peloton Therapeutics, Inc. is an oncology drug discovery and development company focused on advancing first-in-class small molecule therapies that provide patients suffering from life-threatening diseases with new therapeutic options. Peloton is developing a new oral treatment, PT2977, to target late-stage renal cell carcinoma and was recently acquired for an up front payment of approximately $1 billion and potential milestones of an additional $1 billion by Merck & Company, Inc., a recognized leader in cancer research. The acquisition will help advance the development of therapeutic medications for patients with cancer and other life-threatening diseases. Peloton Therapeutics is a wholly-owned subsidiary of Merck & Company, Inc.
Founded in 2011, Acquired in 2019
Exonics Therapeutics is a biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to correct genetic mutations resulting in neuromuscular diseases such as Duchenne muscular dystrophy, a severe form of muscular dystrophy that occurs in 1 out of 3,500–5,000 boys worldwide. The company was recently acquired for a total deal value of approximately $1 billion by Vertex Pharmaceuticals, a global biotechnology company investing in transformative medicines for life-threatening diseases. The acquisition will help accelerate drug development for Duchenne muscular dystrophy and Myotonic Dystrophy Type 1.
Founded in 2017, Acquired in 2019